mitotane - Profile

What are the generic drug sources for mitotane and what is the scope of freedom to operate?

Mitotane is the generic ingredient in one branded drug marketed by Esteve and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for mitotane

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for mitotane

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esteve	LYSODREN	mitotane	TABLET;ORAL	016885-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

EU/EMA Drug Approvals for mitotane

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
HRA Pharma Rare Diseases	Lysodren	mitotane	EMEA/H/C/000521Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.	Authorised	no	no	no	2004-04-28

Mitotane (Lysodren) Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

Where does mitotane sit in the product life cycle and competitive set?

Mitotane is an adrenolytic agent with a focused oncology/endocrinology footprint. Commercially, it is best understood as a high-value, niche branded therapy with limited direct substitution, where pricing power and access dynamics depend on continued manufacturing reliability and regulatory positioning rather than rapid generics substitution alone.

Core commercial positioning

• Indication center: adrenocortical carcinoma (ACC) and adjunct use in cortisol-producing states under specialty regimens depending on jurisdiction.
• Mechanism: adrenolytic steroidogenesis suppression via selective adrenal cytotoxicity and effects on steroid metabolism (clinical relevance is tied to ACC biology and steroid control).
• Treatment model: long-duration dosing with monitoring intensity and dose titration to achieve therapeutic exposure and manage toxicity, which supports specialty-channel retention.

Competitive landscape (how investors should think about “substitution”)

Mitotane competes less on “therapeutic class alternatives” and more on:

• ACC regimen strategy shifts: uptake of modern systemic regimens can reduce mitotane share in some lines, while in other pathways mitotane remains a backbone component due to evidence and clinician familiarity.
• Access and supply continuity: mitotane supply constraints or manufacturing changes can drive short-term price and utilization volatility even without new entrants.
• Switching barriers: monitoring-based dosing and toxicity management create switching friction among clinicians and payers.

What are the demand fundamentals underpinning mitotane?

Mitotane demand is driven by ACC incidence and treatment intensity, then amplified or dampened by guideline adherence, referral patterns, and payer authorization behavior.

Demand drivers

• Incidence pool and referral concentration
  • ACC is rare, so demand scales with concentration of care in tertiary oncology/endocrine centers.
  • Referral center behavior materially affects prescribing rates.
• Line-of-therapy placement
  • Demand depends on whether mitotane is used earlier in the disease course versus later after progression or in combined approaches.
• Treatment duration
  • ACC regimens often require extended treatment and close therapeutic monitoring, supporting sustained utilization per patient.
• Safety and monitoring capacity
  • Dose titration and toxicity management require clinical infrastructure, which can limit uptake in low-experience settings but reinforces loyalty in high-volume centers.

Demand risks

• Regimen displacement
  • If new systemic combinations become preferred across more lines, mitotane share can compress even if patient counts remain stable.
• Payer and formulary pressure
  • In rare disease categories, utilization management can still limit access, particularly when alternatives exist and outcomes are perceived as comparable.
• Supply risk
  • Any interruption in manufacturing or distribution can create backorders and temporary loss of treated patients.

How does mitotane pricing and payer economics typically behave?

Mitotane pricing dynamics are shaped by:

• Branded scarcity and specialty distribution
  • Where branded supply dominates, list price and reimbursement may hold up longer, but net price depends on payer contracting and specialty pharmacy carve-outs.
• Clinical monitoring value
  • Payers often tolerate higher per-patient costs when the drug anchors a regimen and monitoring enables dose optimization and toxicity management.
• Therapeutic exposure monitoring
  • Monitoring practices can be a cost driver but also a quality lever that improves perceived value.

What does the regulatory and exclusivity framework imply for investors?

Mitotane’s investment thesis is tied to regulatory continuity:

• Therapeutic area governance
  • ACC management is strongly guideline-driven and specialty-managed.
• Regulatory permanence
  • The value proposition is less about “label expansion” and more about maintaining effective authorization for its core use and preventing label erosion via shifting standards of care.

From an investor standpoint, the highest-impact regulatory variable is whether the drug remains incorporated into standard ACC treatment pathways in major geographies over a multi-year horizon.

What are the key clinical fundamentals that support or weaken mitotane utilization?

Mitotane’s fundamentals are built around two linked clinical realities: it is a cornerstone drug for ACC in many protocols, and its effectiveness and tolerability depend on therapeutic exposure and careful patient selection.

Practical clinical factors investors should model

• Therapeutic monitoring
  • Outcomes correlate with achieving and maintaining effective drug exposure, which makes adherence to monitoring protocols a utilization determinant.
• Toxicity management
  • Adverse events and dose adjustments can reduce tolerability in some patients, which can shift clinicians toward alternative regimens.
• Patient selection
  • The balance between tumor burden, endocrine profile, and treatment goals influences mitotane’s persistence in regimens.

Evidence quality signal investors track

• Guideline incorporation
  • The strongest demand indicator is whether major guideline bodies continue to position mitotane as a standard component of ACC management.
• Protocol embedding
  • Use in multi-agent or sequential regimens increases durability of demand even when newer agents enter.

What is the patent and exclusivity landscape risk profile?

The investment scenario depends on:

• Whether patent protection materially supports net pricing
  • If patent or data exclusivity has lapsed in major markets, net pricing compression risk rises.
• How many competitors can supply reliably
  • Even when legal exclusivity ends, real-world availability often depends on manufacturing capability and regulatory compliance, which can slow substitution and protect revenue longer than generic legal status alone.

Because mitotane is long-established, investors should treat IP risk as primarily a net price and supply substitution speed problem rather than a binary “loss of exclusivity” step function.

What R&D and pipeline signals matter most for mitotane investors?

For an established small molecule, near-term upside usually comes from:

• Formulation improvements or manufacturing modernization
  • Better stability, supply continuity, or reduced variability can directly impact volume and net revenue.
• Evidence updates
  • New subgroup analyses, biomarker-linked patient selection, or refined dosing strategies can reinforce guideline status.
• Combination strategy optimization
  • If emerging ACC regimens validate combinations that preserve mitotane’s role, share can remain stable.

If mitotane’s role becomes more narrow, the upside shifts from unit volume growth to share-of-access and price resilience.

How should investors build a base-case financial view?

A mitotane-focused model should separate:

• Patient-driven volume
  • ACC incidence treated in mitotane-eligible pathways.
• Treatment intensity
  • Average duration and discontinuation rates, driven by toxicity and response.
• Net price
  • Brand vs generic mix by market and payer contracting.
• Supply and distribution
  • Backorder probability and substitution speed after supply disruptions.

Base-case mechanics (what to quantify)

• Treated patient count
  • Use ACC treated population proxies by geography.
• Mitotane penetration
  • Share of ACC regimens where mitotane remains included by line of therapy.
• Average net revenue per treated patient
  • Net price times dosing duration adjusted for dose reductions and discontinuations.
• Time-to-displacement
  • How quickly clinicians move away when alternative regimens gain adoption.

What are the upside and downside cases?

Upside levers

• Guideline reinforcement of mitotane role
  • Continued incorporation into standard ACC protocols in major markets.
• Supply reliability improvement
  • Reduced interruptions increases treated-patient capture.
• Combination survival gains
  • If new regimens validate mitotane-based strategies, penetration can hold or rise.
• Net price defense
  • Slower generic substitution due to manufacturing complexity and specialty channel barriers.

Downside levers

• Regimen displacement
  • More lines shift to alternatives that deliver comparable or better outcomes with easier monitoring.
• Net price compression
  • Legal or practical competition accelerates, especially if multiple suppliers enter and specialty contracts reset.
• Safety/tolerability constraints
  • If real-world toxicity management improves less than expected, discontinuation rises and effective treated volume falls.
• Supply disruption
  • Production or distribution failures reduce ability to treat.

Investment bottom line: what does mitotane look like as a business today?

Mitotane is an established, specialty-oriented asset whose economics are dominated by:

• Access and supply continuity
• Guideline and clinician embedding in ACC care
• Net price protection versus substitution speed
• Real-world tolerability and monitoring compliance

This profile fits investors seeking stability with targeted catalysts (supply normalization, label reaffirmation, evidence updates) rather than growth driven by rapid uptake expansion.

---

Key Takeaways

• Mitotane is a niche, specialty drug for ACC where demand is driven by treated patient access, regimen embedding, and monitoring practices rather than broad primary-care adoption.
• The main investment sensitivities are net pricing durability, supply reliability, and the pace of regimen displacement as ACC treatment paradigms evolve.
• Upside typically comes from guideline reinforcement, stable or improved supply, and maintained penetration in specialty protocols.
• Downside typically comes from faster-than-expected competitive substitution and broader displacement by alternative ACC regimens.

---

FAQs

1. Is mitotane expected to face rapid demand loss from ACC regimen changes?
   Demand risk is line-of-therapy dependent; displacement can compress penetration even if overall treated ACC populations stay constant.

2. What is the biggest operational driver for mitotane revenue stability?
   Supply continuity and specialty-channel fulfillment, which directly affects the number of patients treated.

3. How should investors model mitotane’s unit economics?
   Separate treated-patient volume, treatment duration and discontinuation, and net price by market and payer contracting.

4. What factors determine whether generic substitution erodes revenue?
   Legal status is only the entry point; real-world erosion depends on competing manufacturers’ regulatory status, supply reliability, and payer contracting outcomes.

5. Which clinical signals most influence payer and clinician behavior for mitotane?
   Continued guideline incorporation, protocol embedding in ACC regimens, and updated evidence on exposure-response and tolerability management.

---

References

[1] National Cancer Institute. “Mitotane.” NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/ (accessed 2026-04-26)
[2] European Medicines Agency. “Lysodren (mitotane) - EPAR.” https://www.ema.europa.eu/ (accessed 2026-04-26)
[3] U.S. Food and Drug Administration. “Lysodren (mitotane) Drug Approval Reports and Label Information.” https://www.accessdata.fda.gov/ (accessed 2026-04-26)
[4] Endocrine Society / Clinical practice guidance resources on adrenocortical carcinoma management (mitotane-centered regimens). https://www.endocrine.org/ (accessed 2026-04-26)